Polyphenols and Gut Bacteria: What Your Microbes Make

Ninety women took a concentrated polyphenol mix for eight weeks, and their cholesterol went up. Their measured level of oxidized LDL went down. This is the story of why both things are true, and what your gut bacteria have to do with it.

Learn Something with Thaena · Episode 36 · 2026 · 17 min read

Why did their cholesterol rise while the damaged LDL fell?

Ninety postmenopausal women with mildly elevated cholesterol, none on medication, took three capsules of a polyphenol extract every evening for eight weeks. The capsules came from pomegranate, Japanese knotweed and red clover. Together they supplied about 600 milligrams of measured polyphenols a day: 312 mg of ellagitannins and ellagic acid, 133 mg of resveratrol, and 166 mg of isoflavones (García-Nicolás 2026).

Then the researchers checked their blood, and the result looks wrong at first.

LDL cholesterol measures how much cholesterol the LDL particles carry. Oxidized LDL is a separate measure: how much LDL in the blood has been chemically altered by oxidation. The trial measured its concentration, not the share of all LDL particles that were oxidized. That altered form is the one implicated in starting and driving the buildup in artery walls, through damage to the vessel lining and uptake by immune cells (Mitra 2011). So the standard number went the "wrong" way, and measured oxidized LDL went the right way. What that means for heart outcomes is not known.

I find that exciting, and I also want to be careful with it. The trial did not measure plaque or heart events, so it cannot tell you the drop in oxidized LDL outweighs the rise in cholesterol. The extract was a high-dose supplement, not food. And all the lipid changes reversed after a four-week washout. What the trial does show is that a single cholesterol number can hide a more complicated picture underneath.

It also showed something else. The biggest drops in oxidized LDL came in specific women: a 65% drop in women whose gut bacteria made equol, and 60% in one cluster of women whose bacteria made urolithin A and equol but no lunularin. These were changes within each group; the trial was not powered to compare the groups with each other, so they point to a pattern rather than prove one. Same capsules, different chemistry, different results. To understand why, you have to follow the polyphenols past the stomach.

What are polyphenols, and where do they come from?

Polyphenols are a huge family of plant compounds built around ring-shaped carbon structures carrying hydroxyl groups. Plants make them for their own reasons. To us they show up as color, bitterness and that dry, puckery feeling in your mouth.

Estimates of how much we eat vary with the diet and the database. Adults eat roughly 200 to 600 mg of flavonoids, one polyphenol family, a day (Alqudah & Claesen 2024). Total polyphenol intake was estimated at 820 mg a day in an older Spanish cohort eating a Mediterranean diet (Tresserra-Rimbau 2013) and about 1,200 mg a day in older adults in Brazil, nearly half of it from coffee (Nascimento-Souza 2016). These are estimates from food questionnaires, so read them as a range.

The family divides into classes, and the class matters, because each one meets a different set of bacteria.

Why do your gut bacteria matter more than the berry?

Most dietary polyphenols are not absorbed in the small intestine, so the bulk of what you eat reaches the colon largely unchanged (Alqudah & Claesen 2024). How much gets through varies a lot by molecule. In a study of people with an ileostomy, only about a third of a dose of chlorogenic acid, the main polyphenol in coffee, was absorbed in the small intestine, while nearly all of its smaller cousin, caffeic acid, was (Olthof 2001). The most abundant polyphenols in the diet are not always the best absorbed (Manach 2004).

So the colon is where most of the action happens. Bacteria there do several jobs in sequence. They strip off the sugars plants attach to polyphenols, and some of those sugar bonds only microbes can cut. Then they pry open the rings, snip the molecule into pieces, and pluck off hydroxyl groups. What comes out the other end is a set of smaller molecules, often phenolic acids, that cross into the blood far more readily than the parent plant compound.

I like to think about it as a kitchen. The plant hands over raw ingredients. Your microbes are the cooks, and what ends up on the plate depends on which cooks are working that day.

Which bacteria break down which polyphenols?

This is where the field has gotten specific in the last few years, down to named species and named enzymes. This is the map as it stands.

A few caveats travel with this table. Much of it comes from bacteria grown in the lab or from germ-free animals given a defined set of microbes: the equol and lignan pathways were shown working inside a living animal in gnotobiotic rats (Matthies 2012; Woting 2010), not people.

Below is one pathway drawn out step by step, with the real chemical structures, starting with kaempferol from your kale.

The cool thing is how much engineering sits inside that one picture. A flavone reductase reduces a double bond in the middle ring. A bacterial chalcone isomerase then contracts that ring into a new shape, maesopsin. Further breakdown yields 4-HPAA and phloroglucinol, with a carbon lost as carbon dioxide (Braune 2016; Schneider & Blaut 2000; Alqudah & Claesen 2024). Osborn and colleagues also searched human stool metagenomes for a set of four marker genes linked to this kind of flavonoid breakdown (Osborn 2022).

Are all polyphenols created equal?

No, and the reason is structural. Two flavonols that look almost identical can become different molecules.

Kaempferol carries one hydroxyl group on its side ring. Quercetin, the flavonol in onions and apples, carries two. Run kaempferol through E. ramulus and you get 4-HPAA. Run quercetin through the same bacterium and you get 3,4-dihydroxyphenylacetic acid (Braune 2001; Schneider & Blaut 2000). One small difference in the starting plant, a different signal in your blood. The review literature describes this: the products depend on the decorations on the parent flavonoid's ring (Alqudah & Claesen 2024).

The chains are another example. Procyanidins are links of smaller flavan-3-ol units, and they come in two architectures. B-type chains are joined by a single bond between units. A-type chains carry an extra ether bond, a second bridge that locks the units together; cranberries are known for their A-type procyanidins. In 2026, researchers showed for the first time that a human gut bacterium, Eggerthella lenta, can open the central ring on the last unit of the B-type chains they tested, two, three and four units long, and of an A-type two-unit chain. A second bacterium, Flavonifractor plautii, showed no detectable activity on these chains, either alone or grown with E. lenta (Halifa 2026). The chains behave differently from single flavan-3-ol units, which the two bacteria can process together.

Pomegranate tells a relay story. Gordonibacter urolithinfaciens takes ellagic acid as far as urolithin C and stops (Selma 2014). A different group, certain Enterocloster species, finishes the job, removing one hydroxyl group from urolithin C to make urolithin A (Beltrán 2023; Pidgeon 2025). If the microbes carrying out the later steps are absent or inactive, the pathway can stop partway.

Why can't everyone make the same metabolites?

Because people carry different bacteria and different genes, and those differences sort people into recognizable groups. Researchers call them metabotypes, and these are the best-sourced numbers we have.

The women in the cholesterol trial were Spanish, and at the start, about 72% made urolithin A, about half made equol and about half made lunularin (García-Nicolás 2026). That is far more equol producers than the "Western 25 to 30%" figure, which tells you how much these numbers move between groups.

Two numbers you may have seen elsewhere do not hold up, so I want to name them. A figure that circulates in the review literature says about 60% of people in the United States make no urolithins. The paper it cites is a Spanish trial of 49 adults, with no US participants, in which about 12% were non-producers (González-Sarrías 2017). And the 4-HPAA figure is about genes in stool samples from two countries. It is not a count of people who make the molecule, and it has no US-only number.

Is your metabotype fixed? Partly. Equol producer status looks fairly stable over time, though some antibiotics can switch it off (Setchell & Clerici 2010). And in one small trial, three of six people who made no urolithins started making them after three weeks of pomegranate extract (González-Sarrías 2017). Six people is a tiny sample, but it is a hopeful one: the cooks can sometimes be recruited.

What do polyphenol metabolites do in the body?

This is the part that makes polyphenols such a good teaching example, because their metabolites have been studied in almost every system of the body. I am going to name the model every time, because a finding in a worm, a mouse, a dish of cells and a person are four different kinds of evidence.

Heart and blood vessels

In the postmenopausal women above, oxidized LDL fell 39% while cholesterol rose (García-Nicolás 2026). A companion analysis of the same women found that urinary TMAO, a microbe-derived compound linked to heart risk, fell in some metabotypes, while TMAO in the blood did not change (Jarrín-Orozco 2026).

Liver and metabolism

When Jan Claesen's group at the Cleveland Clinic added flavonoids to a high-fat diet, 4-HPAA rose in the blood leaving the gut for the liver. Then they gave 4-HPAA on its own, through a slow-release pellet, to male mice already fattened on that diet, and the fat in their livers fell back down. The effect came with activation of AMPK, a cell's fuel sensor (Osborn 2022).

The same group found an elderberry version of the story. Elderberry extract in a high-fat diet improved insulin handling in mice of both sexes and reduced liver fat in males, and only when the gut microbes were intact; antibiotics erased the effect. Clostridium sporogenes made 3-PPA from elderberry-derived compounds, and 3-PPA switched on AMPK in human liver cells in a dish (Alqudah 2025). These are mouse and cell findings, and the cell experiments used one or two samples per group.

Mitochondria and muscle

Urolithin A triggers mitophagy, the process a cell uses to clear out and recycle worn-out mitochondria. In worms it extended lifespan, and in rodents it improved exercise capacity (Ryu 2016). Two human trials followed, both run with the company that sells a urolithin A supplement. In 66 older adults, 1,000 mg a day for four months did not beat placebo on the two main outcomes, walking distance and muscle energy production, though muscle endurance and several blood markers improved (Liu 2022). In 88 middle-aged adults, hamstring strength, measured as average peak torque, rose 12% at 500 mg and 9.8% at 1,000 mg, while the main outcome, peak power, did not change (Singh 2022).

Brain

In rats fed grape seed extract for 11 days, two microbial phenolic acids built up in brain tissue: one rose 3.2-fold and the other 7.7-fold, and more extract meant more in the brain (Wang 2015). In a test tube, the same acids interfered with beta-amyloid, a protein that clumps in Alzheimer's disease, though at concentrations far above what reached the rat brain, and the rats were never tested for memory. Mice given gut microbes from different people made different amounts of these acids from the same flavanols (Ho 2018).

Gut barrier and immune system

Urolithin A, along with a synthetic structural analogue called UAS03, increased the proteins that seal the gut lining and calmed inflammation in cell and mouse models, working through two cell-protective switches, AhR and Nrf2 (Singh R 2019). Human gut-barrier data are not there yet.

Equol and menopause

This thread matters for a lot of our readers. In Japanese postmenopausal women who did not make equol themselves, 10 mg a day of S-equol for 12 weeks cut hot flushes by 58.7%, against 34.5% on placebo (Aso 2012). A one-year pilot found a bone-breakdown marker fell 23.94% on S-equol against 2.87% on placebo (Tousen 2011). A meta-analysis of five trials and 728 women found equol lowered hot-flash scores, though two of the five trials found no benefit (Daily 2019). The S-equol in these trials was a company-developed product, and the trials were mostly in Japanese women, so the results may not carry over to everyone.

Food or extract: does the dose matter?

It does, and it is one of the easiest places to get lost. The cholesterol trial used about 600 mg of measured polyphenols a day from concentrated extracts, all three at once, so no one can say which ingredient did what. The urolithin A trials gave 500 to 1,000 mg of the finished molecule, which skips the microbes. You cannot turn either dose into a number of pomegranates.

Food brings its own complication: it carries fiber too. In a small 2026 blueberry pilot in older adults with mild depressive symptoms, both groups were asked to avoid fiber-rich and anthocyanin-rich foods for three months, and the blueberry powder brought back about 11 grams of fiber a day. Depressive symptoms fell further on average in the blueberry group, but not significantly compared with placebo, and no one can tell whether the fiber or the polyphenols drove it (Millar 2026).

What polyphenols teach us about the whole microbiome

I keep coming back to polyphenols because they make the abstract idea of the microbiome concrete. There is a precursor you can name, from a plant you can picture. There is a bacterium that does a specific chemical step, sometimes with a specific gene. There is a product molecule that travels somewhere in the body and does something measurable there.

And at every link, the outcome depends on context. The same capsule did different things in different women. The same flavonol becomes a different acid depending on one hydroxyl group. The same pomegranate becomes urolithin A, or urolithin C, or almost nothing, depending on which teams are working in your colon. The food is the easy part. The hard part is the ecosystem.

It works the way a farm does. You can plant the best seed in the world, and if the soil has lost its fungi and its worms, that seed only does so much. The plant is the seed here, and your microbes are the soil life that turns it into something the rest of the system can use.

That is also why "eat more polyphenols" is good advice and an incomplete one. More plants, more colors and more variety give your microbes more to work with. Whether they can do the work depends on who is there.

What shows up in Thaena's own source material?

Several of the molecules in this chapter have turned up in the source material ThaenaBiotic® is made from. In 2022, a targeted, calibrated panel (Precion) measured 4-HPAA, 3-hydroxybenzoic acid, 3-(3-hydroxyphenyl)propionic acid and enterolactone at microgram-per-gram levels. An earlier untargeted run (Metabolon, 2021) on freeze-dried material from five screened donors also picked up urolithin A in four of the five. The fifth donor's material had none, the same kind of variation the metabotype studies describe.

These are small amounts, far below the doses used in the studies earlier in this chapter. And 4-HPAA can also come from the amino acid tyrosine, so finding it does not prove it came from a polyphenol (Osborn 2022).

And this is why it matters to how we think. A postbiotic made from healthy donor microbiomes carries chemistry made by a whole community, many molecules at once. Whether that chemistry does anything for the person taking it is the question our research sets out to answer. We believe it is a plausible idea worth testing. It is a thesis, not a proven clinical outcome.

The honest limitations

• Most mechanism findings are animal or cell work. The liver, brain and gut-barrier results come from mice, rats or cells.
• The human trials are small and often company-run. Both urolithin A trials missed their main outcomes, and the equol trials used one company's product.
• The cholesterol trial measured markers, not outcomes. It used a high-dose extract, lasted eight weeks, and its lipid changes reversed after a washout.
• Metabotype numbers move between populations and methods. Read any single percentage as a snapshot of one group.
• Gene counts are not production. Carrying a pathway's genes does not mean you are making the molecule today.
• The bacteria table is a map, not a census. Each row cites a primary paper, but most of those experiments used single bacteria in the lab, and I have not re-read every paper in full for this chapter.

---

Frequently asked questions

Do polyphenols feed gut bacteria?

Polyphenols mostly reach the colon intact, and gut bacteria break them into smaller molecules the body can absorb. In that sense your bacteria use polyphenols as raw material, and what they make from it depends on which species are present (Alqudah & Claesen 2024).

Why do some people make equol and others don't?

Equol is made from soy isoflavones only by specific gut bacteria, so people without those bacteria do not make it. Studies find producers more often in East Asian groups than in Western ones, and some antibiotics can switch production off (Setchell & Clerici 2010).

Can my gut bacteria change which polyphenol metabolites I make?

Sometimes. In one small trial, some people who made no urolithins started making them after three weeks of pomegranate extract, though only six people were in that group (González-Sarrías 2017).

Are polyphenol supplements better than polyphenols from food?

They are different experiments. Supplements deliver high doses of a few compounds, while food delivers many compounds together with fiber, and the trials of each answer different questions (García-Nicolás 2026; Millar 2026).

Which foods contain the most polyphenols?

Coffee, tea, cocoa, berries, pomegranate, leafy greens, citrus, soy, flaxseed and many herbs and spices are rich sources, each carrying a different class of polyphenol (Manach 2004). Variety matters, because each class meets different gut bacteria.

---

The bottom line

---

References

1. Alqudah S, Claesen J (2024). Mechanisms of gut bacterial metabolism of dietary polyphenols into bioactive compounds. Gut Microbes, 16(1). https://doi.org/10.1080/19490976.2024.2426614 · FREE FULL TEXT
2. Song KB, Atkinson C, Frankenfeld CL, et al. (2006). Prevalence of Daidzein-Metabolizing Phenotypes Differs between Caucasian and Korean American Women and Girls. The Journal of Nutrition, 136(5):1347-1351. https://doi.org/10.1093/jn/136.5.1347 · FREE FULL TEXT
3. García-Nicolás M, Jarrín-Orozco MP, Romo-Vaquero M, et al. (2026). Polyphenols increase circulating lipids but improve LDL particle quality and reduce LDL oxidation in postmenopausal women: metabotype- and age-dependent effects in a randomised, placebo-controlled crossover trial. European Journal of Nutrition, 65(5). https://doi.org/10.1007/s00394-026-04027-2 · FREE FULL TEXT
4. Osborn LJ, Schultz K, Massey W, et al. (2022). A gut microbial metabolite of dietary polyphenols reverses obesity-driven hepatic steatosis. Proceedings of the National Academy of Sciences, 119(48). https://doi.org/10.1073/pnas.2202934119 · FREE FULL TEXT
5. Mitra S, Goyal T, Mehta JL (2011). Oxidized LDL, LOX-1 and Atherosclerosis. Cardiovascular Drugs and Therapy, 25(5):419-429. https://doi.org/10.1007/s10557-011-6341-5
6. Tresserra-Rimbau A, Medina-Remón A, Pérez-Jiménez J, et al. (2013). Dietary intake and major food sources of polyphenols in a Spanish population at high cardiovascular risk: The PREDIMED study. Nutrition, Metabolism and Cardiovascular Diseases, 23(10):953-959. https://doi.org/10.1016/j.numecd.2012.10.008
7. Nascimento-Souza MA, de Paiva PG, Pérez-Jiménez J, et al. (2016). Estimated dietary intake and major food sources of polyphenols in elderly of Viçosa, Brazil: a population-based study. European Journal of Nutrition, 57(2):617-627. https://doi.org/10.1007/s00394-016-1348-0
8. Olthof MR, Katan MB, Hollman PC (2001). Chlorogenic Acid and Caffeic Acid Are Absorbed in Humans. The Journal of Nutrition, 131(1):66-71. https://doi.org/10.1093/jn/131.1.66 · FREE FULL TEXT
9. Manach C, Scalbert A, Morand C, et al. (2004). Polyphenols: food sources and bioavailability. The American Journal of Clinical Nutrition, 79(5):727-747. https://doi.org/10.1093/ajcn/79.5.727 · FREE FULL TEXT
10. Braune A, Engst W, Elsinghorst PW, et al. (2016). Chalcone Isomerase from Eubacterium ramulus Catalyzes the Ring Contraction of Flavanonols. Journal of Bacteriology, 198(21):2965-2974. https://doi.org/10.1128/JB.00490-16 · FREE FULL TEXT
11. Braune A, Gütschow M, Engst W, et al. (2001). Degradation of Quercetin and Luteolin by Eubacterium ramulus. Applied and Environmental Microbiology, 67(12):5558-5567. https://doi.org/10.1128/AEM.67.12.5558-5567.2001 · FREE FULL TEXT
12. Schoefer L, Mohan R, Schwiertz A, et al. (2003). Anaerobic Degradation of Flavonoids by Clostridium orbiscindens. Applied and Environmental Microbiology, 69(10):5849-5854. https://doi.org/10.1128/AEM.69.10.5849-5854.2003 · FREE FULL TEXT
13. Halifa R, Dufour C, Cornu A, et al. (2026). Metabolization of Flavan‐3‐ol Oligomers by Eggerthella lenta , a Human Gut Bacterium. Molecular Nutrition & Food Research, 70(19). https://doi.org/10.1002/mnfr.70615 · FREE FULL TEXT
14. Alqudah S, DeLucia B, Osborn LJ, et al. (2025). The diet-derived gut microbial metabolite 3-phenylpropionic acid reverses insulin resistance and obesity-associated metabolic dysfunction. Molecular Metabolism, 102:102272. https://doi.org/10.1016/j.molmet.2025.102272 · FREE FULL TEXT
15. Matthies A, Loh G, Blaut M, et al. (2012). Daidzein and Genistein Are Converted to Equol and 5-Hydroxy-Equol by Human Intestinal Slackia isoflavoniconvertens in Gnotobiotic Rats3. The Journal of Nutrition, 142(1):40-46. https://doi.org/10.3945/jn.111.148247 · FREE FULL TEXT
16. Maruo T, Sakamoto M, Ito C, et al. (2008). Adlercreutzia equolifaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus Eggerthella. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, 58(5):1221-1227. https://doi.org/10.1099/ijs.0.65404-0
17. Selma MV, Tomás-Barberán FA, Beltrán D, et al. (2014). Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. International Journal of Systematic and Evolutionary Microbiology, 64(Pt_7):2346-2352. https://doi.org/10.1099/ijs.0.055095-0
18. Beltrán D, Romo-Vaquero M, Espín JC, et al. (2018). Ellagibacter isourolithinifaciens gen. nov., sp. nov., a new member of the family Eggerthellaceae, isolated from human gut. International Journal of Systematic and Evolutionary Microbiology, 68(5):1707-1712. https://doi.org/10.1099/ijsem.0.002735
19. Beltrán D, Frutos-Lisón MD, García-Villalba R, et al. (2023). NMR Spectroscopic Identification of Urolithin G, a Novel Trihydroxy Urolithin Produced by Human Intestinal Enterocloster Species. Journal of Agricultural and Food Chemistry, 71(31):11921-11928. https://doi.org/10.1021/acs.jafc.3c01675 · FREE FULL TEXT
20. Pidgeon R, Mitchell S, Shamash M, et al. (2025). Diet-derived urolithin A is produced by a dehydroxylase encoded by human gut Enterocloster species. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56266-2 · FREE FULL TEXT
21. Bode LM, Bunzel D, Huch M, et al. (2013). In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. The American Journal of Clinical Nutrition, 97(2):295-309. https://doi.org/10.3945/ajcn.112.049379 · FREE FULL TEXT
22. Woting A, Clavel T, Loh G, et al. (2010). Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiology Ecology, 72(3):507-514. https://doi.org/10.1111/j.1574-6941.2010.00863.x · FREE FULL TEXT
23. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, et al. (2011). Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proceedings of the National Academy of Sciences, 108(16):6615-6620. https://doi.org/10.1073/pnas.1016217108 · FREE FULL TEXT
24. Schneider H, Blaut M (2000). Anaerobic degradation of flavonoids by Eubacterium ramulus. Archives of Microbiology, 173(1):71-75. https://doi.org/10.1007/s002030050010
25. Setchell KD, Clerici C (2010). Equol: History, Chemistry, and Formation. The Journal of Nutrition, 140(7):1355S-1362S. https://doi.org/10.3945/jn.109.119776 · FREE FULL TEXT
26. Tomás-Barberán FA, García-Villalba R, González-Sarrías A, et al. (2014). Ellagic Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health Status. Journal of Agricultural and Food Chemistry, 62(28):6535-6538. https://doi.org/10.1021/jf5024615 · FREE FULL TEXT
27. Iglesias-Aguirre CE, Vallejo F, Beltrán D, et al. (2022). Lunularin Producers versus Non-producers: Novel Human Metabotypes Associated with the Metabolism of Resveratrol by the Gut Microbiota. Journal of Agricultural and Food Chemistry, 70(34):10521-10531. https://doi.org/10.1021/acs.jafc.2c04518 · FREE FULL TEXT
28. Zhang S, Yang J, Luo W, et al. (2026). Diet, gut microbiota and urinary metabolite profiles associated with lunularin metabotypes in young Chinese adults. Food & Function, 17(9):3916-3931. https://doi.org/10.1039/d6fo00717a
29. González‐Sarrías A, García‐Villalba R, Romo‐Vaquero M, et al. (2017). Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight‐obese individuals consuming pomegranate: A randomized clinical trial. Molecular Nutrition & Food Research, 61(5). https://doi.org/10.1002/mnfr.201600830
30. Jarrín-Orozco MP, García-Nicolás M, Romo-Vaquero M, et al. (2026). Precision health targeting TMAO in postmenopausal women: polyphenol effects modulated by urolithin A and equol metabotypes in a randomised, placebo-controlled crossover trial. Food & Function, 17(4):2037-2049. https://doi.org/10.1039/d5fo05461c · FREE FULL TEXT
31. Ryu D, Mouchiroud L, Andreux PA, et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine, 22(8):879-888. https://doi.org/10.1038/nm.4132 · FREE FULL TEXT
32. Liu S, D’Amico D, Shankland E, et al. (2022). Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults. JAMA Network Open, 5(1):e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279 · FREE FULL TEXT
33. Singh A, D’Amico D, Andreux PA, et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 3(5):100633. https://doi.org/10.1016/j.xcrm.2022.100633 · FREE FULL TEXT
34. Wang D, Ho L, Faith J, et al. (2015). Role of intestinal microbiota in the generation of polyphenol‐derived phenolic acid mediated attenuation of Alzheimer's disease β‐amyloid oligomerization. Molecular Nutrition & Food Research, 59(6):1025-1040. https://doi.org/10.1002/mnfr.201400544 · FREE FULL TEXT
35. Ho L, Zhao D, Ono K, et al. (2019). Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity. The Journal of Nutritional Biochemistry, 64:170-181. https://doi.org/10.1016/j.jnutbio.2018.10.019 · FREE FULL TEXT
36. Singh R, Chandrashekharappa S, Bodduluri SR, et al. (2019). Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nature Communications, 10(1). https://doi.org/10.1038/s41467-018-07859-7 · FREE FULL TEXT
37. Aso T, Uchiyama S, Matsumura Y, et al. (2012). A Natural S -Equol Supplement Alleviates Hot Flushes and Other Menopausal Symptoms in Equol Nonproducing Postmenopausal Japanese Women. Journal of Women's Health, 21(1):92-100. https://doi.org/10.1089/jwh.2011.2753 · FREE FULL TEXT
38. Tousen Y, Ezaki J, Fujii Y, et al. (2011). Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women. Menopause, 18(5):563-574. https://doi.org/10.1097/gme.0b013e3181f85aa7
39. Daily JW, Ko BS, Ryuk J, et al. (2019). Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Medicinal Food, 22(2):127-139. https://doi.org/10.1089/jmf.2018.4265
40. Millar CL, Chopra MP, Morgan X, et al. (2026). A pilot study of daily blueberry intake modulates the gut microbiota enzyme commissions in older, sedentary adults with mild depressive symptoms. The Journal of nutrition, health and aging, 30(10):100958. https://doi.org/10.1016/j.jnha.2026.100958 · FREE FULL TEXT